ARCHIVES

CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely

This article is from The Cancer Letter archive.

Vol. 29 No. 21 | May 23, 2003

Download PDF Visit The Full Archive

Related Articles

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

Degarelix Approved For Advanced Prostate Cancer

January 30, 2009

Health Disparities Between Minorities Too Large, Shalala Says

March 27, 1998

New Therapies For Genitourinary Cancers In Clinical Testing Presented At ASCO

July 25, 2003

Reports Propose Stricter Rules To Protect Research Participants

October 11, 2002

ASSIST Gets Extra Year Of Funding While NCI Considers Role In Tobacco Control

January 17, 1997